来源：环球网 近年来，无糖饮料与零卡食品悄然占据超市货架，成为越来越多人饮食的一部分。一边享受甜味，一边 控制热量摄入——这看似矛盾的体验，背后正是甜味剂在发挥作用。从饮料到零食，甚至日常口腔护理 产品，甜味剂已深入我们的生活，成为现代食品科技回应健康需求的重要载体。 甜味剂的进化史 甜味剂的诞生与应用，是食品科技提升生活品质的又一经典范例。中国中医科学院医学实验中心代金刚 研究员表示："它不仅为我们提供了新的甜味选项，也呼应了现代人对健康与口感多样化的双重追求。 这既是现代食品技术创新的成果，也是富足的生活方式走向多元的见证。" 如今，甜味剂已融入日常：无糖饮料、低糖酸奶、零卡零食，甚至牙膏中都有它的身影。它悄然改变着 我们的饮食结构，让"甜而不腻、健康无负担"逐渐成为新的生活态度和个人品味。 申港证券的研报《绽放味蕾之花-甜味剂行业深度报告》中指出，甜味剂并非"黑科技"，它们来源多 样：有的取自植物，如甜菊糖苷、罗汉果甜苷；有的通过发酵制成，如赤藓糖醇；也有人工合成的，如 三氯蔗糖、安赛蜜。它们的共同特点是：甜度高、热量低，轻松享受甜味。 代金刚进一步解释道："以三氯蔗糖为例，甜度约为蔗糖的600倍，几乎 ...

36氪获悉，合成生物领域企业瑞芬生物已完成亿元级C轮融资。本次融资由兴湘资本领投，瑞鹏象屿基 金跟投，募集资金将用于商业化拓展和新产能建设。易凯资本为本轮融资的独家财务顾问。 近些年，在丰富营养、追求天然、降低负担等新健康消费理念的影响下，头部食品企业和新锐品牌对于 原料、配料的需求越发多元化，如何围绕核心原料构建创新配方，通过提供创新的解决方案协助其占据 更多的市场份额、更好的品牌影响力，成为上游原料供应商亟需解决的重要议题。 瑞芬生物成立于2007年，致力于追求纯净、高效、清洁的天然成分制备技术，推动天然原料的可持续发 展。创始人、董事长兼CEO王晓韵毕业于浙江大学，具备近20年植物提取物、天然甜味剂产业转化经 验。 王晓韵认为，天然成分原料供应商正面临整体升级，供应商应该不断进化，且具备围绕核心原料构建兼 具"口味、功能、应用、外观、成本"能力的创新解决方案。基于此，瑞芬生物以植物提取+合成生物技 术为基础，已构建天然甜味剂平台，天然功能性平台和药用辅料平台三大产品平台。 据介绍，瑞芬生物现已与多家头部科研院所合作，形成了稳定的科技成果产业化网络。公司与中科院天 工所和上海交大微生物代谢国家重点实验室合 ...

Core Viewpoint - The appointment of Wang Qiang as the new chairman of Baolingbao follows the resignation of the previous chairman, Dai Sijue, highlighting significant management changes within the company amid industry challenges [1][2] Management Changes - Baolingbao has experienced nearly 10 changes in its board and senior management positions within the year, indicating a strategic shift in response to operational pressures [1][2] - The resignation of Dai Sijue, who was noted as the youngest chairman in A-shares, reflects the need for management transformation due to competitive pressures in the industry [1][2] - The company has introduced several experienced management talents to enhance operational efficiency and focus on high-margin businesses [2] Industry Context - The functional sweetener industry is facing a "winter" period characterized by overcapacity and price wars, particularly following the surge in the sugar-free beverage market since 2021 [1][3] - The industry is undergoing a transition from high-intensity artificial sweeteners to natural and functional sweeteners to meet health demands, with rapid development in natural sweeteners like steviol glycosides and monk fruit sugar [3] Financial Performance - In 2023, Baolingbao's sales of sugar alcohol products plummeted by 41.79%, with a gross margin dropping to -9.65%, prompting management adjustments [1] - For the first three quarters of 2024, Baolingbao reported revenue of 2.126 billion yuan, a year-on-year increase of 15.98%, and a net profit of 134 million yuan, up 32.58% [4] - The core products, including prebiotics, dietary fiber, and sugar-reducing sweeteners, accounted for 61.5% of revenue and 68.6% of gross profit, indicating a focus on high-margin segments [4]

Core Insights - The appointment of Wang Qiang as the new chairman of Baolingbao follows the resignation of the previous chairman, Dai Sijue, highlighting significant leadership changes within the company amid industry challenges [1][4] - The frequent turnover of nearly 10 executives in Baolingbao this year reflects broader struggles within the functional sweetener industry, which is facing pressures to balance short-term performance with long-term strategic investments [1][5] Company Developments - Dai Sijue resigned for personal reasons, marking a shift in Baolingbao's management in response to competitive pressures in the market, particularly after a significant drop in sales and profitability in 2023 [4][9] - Wang Qiang, who has extensive experience in multinational corporations, was brought in to lead the company through a strategic transformation and enhance operational efficiency [4][5] - The company has seen a drastic decline in sales of its sugar alcohol products, with a 41.79% year-on-year drop in 2023 and a negative gross margin of -9.65% [4][9] Industry Context - The functional sweetener industry is experiencing intense competition, with many companies undergoing leadership changes as they adapt to market conditions [6][7] - The industry is characterized by a clear competitive hierarchy, with companies like Lian Biological and Jinhe Industrial leading the market, while Baolingbao and others are positioned in the mid-tier [7][8] - The shift towards natural and functional sweeteners is evident, with companies focusing on product differentiation and technological upgrades to meet health demands [8][9] Financial Performance - Baolingbao reported a revenue of 2.126 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 15.98%, and a net profit of 134 million yuan, up 32.58% [9] - The core products, including prebiotics, dietary fibers, and sugar-reducing sweeteners, accounted for 61.5% of the company's revenue, indicating a strategic focus on high-margin products [9]

Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., specializes in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - Main business revenue composition includes sugar alcohols (88.22%), functional sugars (8.59%), and others (2.93%) [7]. - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating strong innovation capabilities and market share [2]. Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - Cumulative cash dividends since the company's A-share listing amount to 608 million yuan, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - The company benefits from a 69.27% share of overseas revenue, aided by the depreciation of the Renminbi [3]. - The company is involved in distributed photovoltaic power generation projects, which reduce reliance on traditional energy sources and lower greenhouse gas emissions [2]. Group 4: Stock Performance - As of December 1, the stock price increased by 0.29%, with a trading volume of 22.05 million yuan and a market capitalization of 5.606 billion yuan [1]. - The average trading cost of the stock is 29.42 yuan, with a current support level at 27.27 yuan [6].

Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., is engaged in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The main products of the company include erythritol and compound sugars, with a revenue composition of 88.22% from sugar alcohols, 8.59% from functional sugars, 2.93% from other categories, and 0.26% from glycosides [7]. - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - As of November 20, the number of shareholders increased by 5.13% to 16,300, with an average of 7,977 circulating shares per person, a decrease of 4.88% [7]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - The company has distributed a total of 608 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [2]. - The company benefits from a significant overseas revenue share of 69.27%, aided by the depreciation of the Chinese yuan [3]. Group 4: Recent Market Activity - On November 28, the company's stock price increased by 0.11%, with a trading volume of 28.5 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 5.59 billion yuan [1]. - The stock's average trading cost is 29.43 yuan, with the current price near a support level of 27.27 yuan [6].

Core Viewpoint - Sanwei Biological announced that its erythritol exports to the EU market have been significantly impacted due to the highest applicable tax rate in the EU anti-dumping investigation [2] Group 1: Business Adjustments - In response to the challenges posed by the EU anti-dumping investigation, the company has adjusted its existing business model [2] - The company has introduced a blended product with erythritol content below 90% to EU customers, which has gradually increased customer acceptance and shipment volume [2] - The company is constructing a corn processing production line to address the high prices of alternative starch and is preparing for a review in compliance with EU trade rules to protect its legal rights [2]

Core Viewpoint - The announcement from Sanwei Biological highlights the significant impact of the U.S. Department of Commerce's preliminary ruling on the anti-dumping investigation of erythritol, which imposes a preliminary tax rate of 450.64% on the company, creating barriers for exports to the U.S. market [2] Group 1 - On July 15, 2025, the U.S. Department of Commerce announced the preliminary ruling in the anti-dumping investigation, listing the company as a mandatory respondent [2] - The final ruling, originally scheduled for December 1, 2025, is expected to be delayed due to the recent U.S. government shutdown [2] - The preliminary ruling has created a significant obstacle for Chinese erythritol exports to the U.S., leading to a temporary tightening of supply in the U.S. market [2] Group 2 - Despite the challenges in the U.S. market, demand in North America remains, and imports of the company's products from neighboring countries like Canada and Mexico have gradually increased [2] - The company's third-quarter sales revenue showed a year-on-year increase, although the proportion of overseas revenue slightly decreased compared to the first half of the year [2] - Export growth to other countries and regions has partially offset the decline in the U.S. market [2]

证券日报网讯三元生物11月25日发布公告，在公司回答调研者提问时表示，今年以来，受市场利率下调 等因素影响，公司投资收益同比显著减少。为了提升经营业绩，公司在成本管控、生产优化及市场布局 等方面持续推进多项举措：通过丰富产品结构以摊薄固定成本，增加新的利润来源；通过光伏发电和设 备节能改造等方式降低能耗成本；持续提升生产线自动化水平，优化人员配置，确保技术人员能够更好 地支持新产品的产业化；在基础研发和工艺优化方面取得阶段性进展，赤藓糖醇的转化率进一步提升， 并围绕新产品形成系统的专利布局；同时，积极拓展国内市场及东南亚、印度、中东等新兴市场，部分 地区的增量需求对欧美市场波动形成一定对冲作用。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯三元生物11月25日发布公告，在公司回答调研者提问时表示，公司出口至美国市场的赤藓 糖醇价格维持在每公斤一美元多的水平，未发生显著变化。针对美国"双反"调查，公司已聘请专业律师 团队依法参与应诉，积极就调查程序及裁定依据提出意见。与此同时，来自美国市场的相关客户亦就调 查期内美国本土企业未生产的有机赤藓糖醇、复配糖和非转基因赤藓糖醇等产品向美国商务部提交了异 议材料，通过法律途径维护其正当权益。公司将继续关注调查进展及相关政策变化，在依法合规的前提 下积极寻求合理的发展空间。 ...